AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug

Health insurer Highmark inked an outcomes-based contract with AstraZeneca (NYSE:AZN) for Symbicort, the pharmaceutical company’s drug designed to treat asthma and chronic obstructive pulmonary disease. Highmark said its contract with AstraZeneca is one of the first outcomes-based deals involving a respiratory drug and will apply to commercial members of its national and core markets in Pennsylvania, West Virginia and Delaware. Get the full story at our sister site, Drug Delivery Business News. The post AstraZeneca inks outcomes-based contract with Highmark for COPD, asthma drug appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Pharmaceuticals Respiratory Wall Street Beat AstraZeneca plc Source Type: news

Related Links:

The five Muscarinic Acetylcholine (ACh) receptors are G-protein coupled receptors (M1R-M5R). M1R, M3R and M5R selectively couple to Gq/G11; M2R and M4R selectively couple to Gi/Go. M3 muscarinic ACh receptors are present in the central nervous system and the periphery.M3R knockout mice are viable and fertile, and have no major morphological abnormalities. They have a lean phenotype. This results from a combination of reduced caloric intake and increased energy expenditure. They eat less food than wild-type mice, possibly because a central cholinergic pathway that stimulates food intake is disrupted. They also expend more e...
Source: NIDDK Research Resources - Category: Endocrinology Source Type: research
Abstract Once neglected in research and underappreciated in practice, there is renewed interest in bronchiectasis unrelated to cystic fibrosis. Bronchiectasis is a chronic lung disease characterised by chronic cough, sputum production and recurrent pulmonary exacerbations. It is diagnosed radiologically on high resolution computed tomography chest scan by bronchial dilatation (wider than the accompanying artery). The causes of bronchiectasis are diverse and include previous respiratory tract infections, chronic obstructive pulmonary disease, asthma, immunodeficiency and connective tissue diseases. A large proporti...
Source: Med J Aust - Category: General Medicine Authors: Tags: Med J Aust Source Type: research
(Natural News) Outdoor air pollution is detrimental to a person’s health – this much is certain. Various studies link it to major health conditions such as heart disease, stroke, cancer, asthma and chronic obstructive pulmonary disease. Now, researchers from the Washington University School of Medicine in St. Louis and the Veterans Affairs (VA) St. Louis Health Care...
Source: - Category: Consumer Health News Source Type: news
This study analyzed associations between a variety of human diseases and trace metals, PCBs, and PAHs in soil, groundwater, sediment, and fish. Contaminant spatial data at the county level from Virginia were used in ArcGIS to identify these associations among socially vulnerable populations. The neurologic and psychiatric disorders and cognitive markers were associated with numerous metals in groundwater/soil and/or aquatic system contaminants. Cancer death rates, fetal deaths, and infant deaths were also related to multiple environmental exposures from both categories of exposure. In contrast, many of the chronic diseases...
Source: Environmental Geochemistry and Health - Category: Environmental Health Source Type: research
Adherium, a Silicon Valley firm, is releasing its Hailie system for inhaler monitoring in the United States. The company received FDA clearance to sell the product over the counter, allowing patients to work toward improved compliance with regards to...
Source: Medgadget - Category: Medical Devices Authors: Tags: Medicine Pediatrics Source Type: blogs
Adherium (ASK:ADR) today launched over-the-counter sales of its Hailie digital inhaler add-on in the U.S. The sensor is designed to integrate directly with prescription inhaler medications, sending adherence reminders and relevant data to a user’s smartphone to assist in managing chronic respiratory conditions like asthma and COPD. Get the full story at our sister site, Drug Delivery Business News. The post Adherium launches over-the-counter inhaler sensor in US appeared first on MassDevice.
Source: Mass Device - Category: Medical Devices Authors: Tags: Drug-Device Combinations Food & Drug Administration (FDA) Pharmaceuticals Respiratory Wall Street Beat Adherium Limited Source Type: news
Individual risk factors play a more significant role in the development of ACOS than exposure to fine particulate matter Related items fromOnMedica Adiponectin level link to asthma Pregnant women urged to have swine flu jab Stress in pregnancy may raise asthma risk Target rates for caesareans may be too low Fewer than ever women smoke at point of birth
Source: OnMedica Latest News - Category: UK Health Source Type: news
Chronic airflow obstruction (CAO) is the primary characteristic of Chronic obstructive pulmonary disease (COPD) but is also seen in chronic asthma.
Source: Respiratory Medicine - Category: Respiratory Medicine Authors: Source Type: research
This study evaluated patients ’ experiences with fluticasone furoate/vilanterol (FF/VI) combination therapy in UK patients with asthma or chronic obstructive pulmonary disease (COPD).MethodsParticipants aged ≥ 18 years, with self-reported, physician-diagnosed asthma or COPD (≥ 1 year) who had been receiving FF/VI (≥ 3 months) were recruited from UK primary care. This two-phase, mixed-methods study consisted of a semi-structured, telephone-interview phase (qualitative) and a self-completed online/paper-survey phase (quantitative).ResultsThe telephone-interview phase include...
Source: Advances in Therapy - Category: Drugs & Pharmacology Source Type: research
More than 4 in 10 women with asthma developed chronic obstructive pulmonary disease (COPD), and heavy smoking and obesity were among the significant risk factors, a new study found.
Source: WebMD Health - Category: Consumer Health News Source Type: news
More News: Asthma | AstraZeneca | Chronic Obstructive Pulmonary | Contracts | Insurers | Respiratory Medicine | Symbicort